Cited by 26Abdominal vascular conditions and treatmentsSepsis Diagnosis and TreatmentAbdominal Surgery and Complications

Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: Results from a prospective observational study

Open access
Rittgerodt, Nina, Pape, Thorben, Busch, Markus, Becker, Lena S., Schneider, Andrea, Wedemeyer, Heiner, Seeliger, Benjamin, Schmidt, Julius +10 more·2022·Critical Care

Published version of a preprint

Abstract

BACKGROUND: Non-occlusive mesenteric ischemia (NOMI) is a life-threatening condition occurring in patients with shock and is characterized by vasoconstriction of the mesenteric arteries leading to intestinal ischemia and multi-organ failure. Although minimal invasive local intra-arterial infusion of vasodilators into the mesenteric circulation has been suggested as a therapeutic option in NOMI, current knowledge is based on retrospective case series and it remains unclear which patients might benefit. Here, we prospectively analyzed predictors of response to intra-arterial therapy in patients with NOMI. METHODS: This is a prospective single-center observational study to analyze improvement of ischemia (indicated by reduction of blood lactate > 2 mmol/l from baseline after 24 h, primary endpoint) and 28-day mortality (key secondary endpoint) in patients with NOMI undergoing intra-arterial vasodilatory therapy. Predictors of response to therapy concerning primary and key secondary endpoint were identified using a) clinical parameters as well as b) data from 2D-perfusion angiography and c) experimental biomarkers of intestinal injury. RESULTS: A total of 42 patients were included into this study. At inclusion patients had severe shock, indicated by high doses of norepinephrine (NE) (median (interquartile range (IQR)) 0.37 (0.21-0.60) μg/kg/min), elevated lactate concentrations (9.2 (5.2-13) mmol/l) and multi-organ failure. Patients showed a continuous reduction of lactate following intra-arterial prostaglandin infusion (baseline: (9.2 (5.2-13) mmol/l vs. 24 h: 4.4 (2.5-9.1) mmol/l, p < 0.001) with 22 patients (52.4%) reaching a lactate reduction > 2 mmol/l at 24 h following intervention. Initial higher lactate concentrations and lower NE doses at baseline were independent predictors of an improvement of ischemia. 28-day mortality was 59% in patients with a reduction of lactate > 2 mmol/l 24 h after inclusion, while it was 85% in all other patients (hazard ratio 0.409; 95% CI, 0.14-0.631, p = 0.005). CONCLUSIONS: A reduction of lactate concentrations was observed following implementation of intra-arterial therapy, and lactate reduction was associated with better survival. Our findings concerning outcome predictors in NOMI patients undergoing intra-arterial prostaglandin therapy might help designing a randomized controlled trial to further investigate this therapeutic approach. Trial registration Retrospectively registered on January 22, 2020, at clinicaltrials.gov (REPERFUSE, NCT04235634), https://clinicaltrials.gov/ct2/show/NCT04235634?cond=NOMI&draw=2&rank=1 .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13054-022-03962-w

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Continuous prostaglandin infusion can reduce lactate concentrations and enhance survival in nonocclusive mesenteric ischemia.

    “Recent studies indicate continuous prostaglandin infusion can reduce lactate concentrations and enhance survival in nonocclusive mesenteric ischemia [35].”

    From Revascularization Strategies for Acute and Chronic Mesenteric Ischemia: A Narrative Review (2024) · cites this paper as [35]

    The Results (Clinical endpoints; page not provided) report that lactate concentrations declined after continuous intra-arterial prostaglandin infusion. The Conclusions and Discussion (pages not provided) associate lactate reduction with better survival, but this uncontrolled study does not establish that the infusion itself enhances survival. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In a study of 42 patients with NOMI, intra-arterial prostaglandin E1 gave a better reduction in lactate levels than standard care.

    “In a study of 42 patients with NOMI, intra-arterial prostaglandin E1 gave a better reduction in lactate levels than standard care.”

    From Editor's Choice - European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Diseases of the Mesenteric and Renal Arteries and Veins. (2025) · cites this paper as [201]

    Table 1 in Results identifies a cohort of 42, and the Clinical endpoints section reports that lactate levels declined after intra-arterial prostaglandin therapy. But the Discussion explicitly says the study lacked a control group, so it cannot establish a better lactate reduction than standard care. (LLM, conf=0.92)

    Experimental — accuracy not yet measured
  • The overall 28 day mortality rate was 30/42 (71.4%).

    “The overall 28 day mortality rate was 30/42 (71.4%). 201”
  • Endovascular revascularization can have similar perioperative outcomes to open surgery but higher rates of late technical failure with symptom recurrence and need for reintervention.

    “comparative studies have suggested that endovascular revascularization can have similar perioperative outcomes to traditional open surgical interventions but demonstrate higher rates of late technical failure with symptom recurrence and need for reintervention [35,70].”

    From Revascularization Strategies for Acute and Chronic Mesenteric Ischemia: A Narrative Review (2024) · cites this paper as [35]

    The Background describes a study of intra-arterial vasodilator therapy for non-occlusive mesenteric ischemia, not a comparison of endovascular revascularization with open surgery. The Discussion states that the study lacked a control group. Searches for perioperative comparisons, late technical failure, symptom recurrence, and reintervention found no passage addressing those claims (page numbers unavailable). (LLM, conf=0.78)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rittgerodt, N., Pape, T., Busch, M., Becker, L. S., Schneider, A., Wedemeyer, H., Seeliger, B., Schmidt, J., Hunkemöller, A. M., Fuge, J., Knitsch, W., Fegbeutel, C., Gillmann, H.-J., Meyer, B. C., Hoeper, M. M., Hinrichs, J. B., David, S., & Stahl, K.
Affiliations
Medizinische Hochschule Hannover (DE)
Corresponding author
Stahl, Klaus
Venue
Critical Care
Published
2022-04-04
Volume
26
Issue
1
Pages
92-92
ISSN
1364-8535 (ISSN-L)
OpenAlex
W4226097275
Cited by
26
References
30
Citations by year
2026: 5 · 2025: 4 · 2024: 6 · 2023: 9 · 2022: 2
FWCI
5.02
Type
journal article
Language
en
Open access
Locations
  • Critical Care (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Deutsche Forschungsgemeinschaft (DA1209/4-3)
  • Medizinische Hochschule Hannover (MHH)
Topics
  • Health Sciences › Medicine › Surgery › Abdominal vascular conditions and treatments
  • Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Abdominal Surgery and Complications
Keywords
nonocclusive mesenteric ischemia, prostaglandin infusion, severe shock, predictors of treatment response, blood lactate, norepinephrine dose, 28-day mortality, multiple organ failure, intestinal ischemia, mesenteric vasoconstriction
MeSH terms
Humans, Prospective Studies, Retrospective Studies, Shock, Vasodilation, Mesenteric Ischemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review